Symposium hosted by Guillermo
Garcia-Manero, M.D. and Eric Winer, M.D.
Academics and industry professionals will
gather virtually on September 22, 2023
LEXINGTON, Mass., Sept. 12,
2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS),
a biotechnology company focused on the development of emavusertib,
an orally available, small molecule IRAK4 inhibitor for the
treatment of hematologic malignancies, today announced
the 2nd Symposium on IRAK4 in Cancer taking place
virtually on September 22, 9:00am-1:00pm ET.
Hosted by Dr. Guillermo
Garcia-Manero and Dr. Eric
Winer, this symposium will focus on IRAK4, a key protein in
the innate immune response and an emerging target in the treatment
of hematologic malignancies and solid tumors. Experts across
academia and industry will discuss IRAK4's biological and
immunological roles as well as the promising role of targeting
IRAK4 in cancer therapeutics.
"Following the success of last year's symposium on IRAK4 in
cancer, Curis is pleased to continue its sponsorship of the Annual
IRAK4 Symposium," said James
Dentzer, President, and Chief Executive Officer of Curis.
"As a leader in IRAK4 inhibition in oncology with emavusertib, we
are honored to provide a forum for discussing the biology of the
IRAK4 pathway and IRAK4 inhibition in the research and development
of therapies to benefit patients living with cancer."
Symposium hosts:
- Guillermo Garcia-Manero, M.D. -
Symposium Co-Chair - Professor, Department of Leukemia; Chief,
Section of Myelodysplastic Syndromes and Deputy Chair,
Translational Research, Department of Leukemia, Division of Cancer
Medicine, The University of Texas MD
Anderson Cancer Center
- Eric Winer, M.D. – Symposium
Co-Chair – Clinical Director, Adult Leukemia Institute Physician,
Dana-Farber Cancer Institute; Assistant Professor of Medicine,
Harvard Medical School
Joining our hosts will be the following speakers and
participants:
- Omar Abdel-Wahab, M.D. - Edward
P. Evans Chair in MDS, Director, Memorial Sloan Kettering Cancer
Center (MSK) for Hematologic Malignancies; Member, Human Oncology
and Pathogenesis Program & Leukemia Service
- Claudio Cerchione, M.D., Ph.D. -
Hematologist, Istituto Scientifico Romagnolo per lo Studio e la
Cura dei Tumori (IRST) IRCCS
- Bentley Doonan, M.D., M.S. -
Assistant Professor, Division of Hematology & Oncology,
University of Florida College of
Medicine
- Matthew Galsky, M.D. - Professor
of Medicine (Hematology and Medical Oncology), Director of
Genitourinary Medical Oncology, Co-Director of the Center of
Excellence for Bladder Cancer, Associate Director for Translational
Research, Tisch Cancer
institute
- Christian Grommes, M.D. –
Associate Professor of Neurology, Weill Cornell Medical College;
Assistant Professor of Neuroscience, Brain and Mind Research
Institute, Weill Cornell Medical College; Neuro-oncologist,
Memorial Sloan-Kettering Cancer Center
- Kian-Huat Lim, M.D., Ph.D. -
Associate Professor, Division of Oncology, Department of Medicine,
Washington University School of
Medicine in St. Louis
- Daniel Starczynowski, Ph.D. – Institute Associate Director for
Basic Science Research, University of
Cincinnati Cancer Center; Co-Chief Scientific Officer,
Innovations Ventures; Katherine Stewart Waters Endowed Chair of
Hematologic Malignancies, Professor in Pediatrics, Co-Leader,
Hematologic Malignancies Program, Cincinnati Children's
Hospital
- Richard Stone, M.D. – Chief of
Staff, Dana-Farber Cancer Institute; Director of Translational
Research, Adult Acute Leukemia Program, Dana-Farber Cancer
Institute; Professor of Medicine, Harvard
Medical School
- Amit Verma, M.B.B.S. –
Professor, Department of Oncology (Medical Oncology), Department of
Medicine (Oncology & Hematology), and Department of
Developmental & Molecular Biology, Albert Einstein College of Medicine; Director,
Division of Hemato-Oncology, Montefiore Department of Oncology;
Associate Director, Translational Science, Montefiore Einstein
Cancer Center; Co-Director, Montefiore Einstein Blood Cancer
Institute
The virtual event will address topics including the biology of
the IRAK4 pathway and the potential of IRAK4 inhibition in both
hematologic malignancies and solid tumors. Presentations and a
panel discussion will address IRAK4 biology and clinical experience
with IRAK4 inhibition, the potential to overcome treatment
resistance, biomarkers, and next steps in the field. To learn
more about this free-to-attend symposium and register, please
visit https://cvent.me/YWvRDD
About Curis, Inc.
Curis is a biotechnology
company focused on the development of emavusertib, an orally
available, small molecule IRAK4 inhibitor for the treatment of
hematologic malignancies. In 2015, Curis entered into a
collaboration with Aurigene in the areas of immuno-oncology and
precision oncology. As part of this collaboration, Curis has
exclusive licenses to oral small molecule antagonists of immune
checkpoints including the VISTA/PDL1 antagonist CA-170, and the
TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor,
emavusertib (CA-4948). Emavusertib is currently undergoing testing
in the Phase 1/2 TakeAim Lymphoma study in patients with
hematologic malignancies, such as non-Hodgkin's lymphoma and other
B cell malignancies, both as a monotherapy and in combination with
the BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia
study in patients with acute myeloid leukemia and myelodysplastic
syndrome, for which it has received Orphan Drug Designation from
the U.S. Food and Drug Administration. In addition, Curis is
engaged in a collaboration with ImmuNext for development of
CI-8993, a monoclonal anti-VISTA antibody. Curis is also party to a
collaboration with Genentech, a member of the Roche Group, under
which Genentech and Roche are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information,
visit Curis' website at www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-announces-date-for-the-2nd-symposium-on-irak4-in-cancer-301924448.html
SOURCE Curis, Inc.